Today: 13 June 2026
Pro Medicus share price jumps nearly 8% as ASX:PME steadies after post-results whiplash
17 February 2026
1 min read

Pro Medicus share price jumps nearly 8% as ASX:PME steadies after post-results whiplash

SYDNEY, Feb 17, 2026, 17:27 AEDT — The market has closed.

Pro Medicus Ltd closed up 7.7% at A$125.96 on Tuesday, topping Australia’s S&P/ASX 200, which notched a 0.24% gain.

The rebound stands out as traders keep wrestling with how to price “growth” when expensive software stocks keep taking a hit. With Lunar New Year thinning out activity across Asia and Wall Street dark for Presidents’ Day, local momentum and earnings are doing most of the work setting direction. Reuters

For Pro Medicus, it’s all about execution now—turning those big hospital deals from signatures into working, billable systems, and doing it fast.

Pro Medicus reported a 28.4% jump in revenue to A$124.8 million for the half-year ended Dec. 31, according to its Feb. 12 ASX filing. Underlying profit before tax climbed 29.7% to A$90.7 million. Net profit after tax surged to A$171.2 million, driven by A$149.1 million in unrealised gains from its 4D Medical stake—those gains haven’t been realised as cash. The company announced a fully franked interim dividend of 32 cents a share and said it continues to carry no debt.

Chief executive Sam Hupert noted the company’s biggest “go-live” happened late in the half, which meant “it had limited financial impact in the half but will have in the second half.” Hupert called Pro Medicus “a capital-light, software-only model,” pointing this out while AI-driven headlines sent software valuations swinging. Company Announcements

Pro Medicus develops imaging software for radiologists and clinicians—think storage, processing, and reading of medical scans. The RIS manages workflow, while the PACS acts as both library and viewer for images.

Revenue at the company tends to swing, since large deployments rarely land on schedule. If a rollout slips, usage fees and support sales get deferred to another quarter—contract or no contract.

Still, risks remain. A stumble in execution, and suddenly doubts about growth resurface. Investors, for their part, are quick to discount any one-off gains when sizing up real earnings strength.

Shares of Pro Medicus finished the session at A$125.96, bouncing around from A$116.98 up to A$127.55, per Intelligent Investor. Investors have their eyes on Feb. 26—the ex-dividend date for the interim 32-cent payout. That dividend lands on March 20.

Stock Market Today

  • Ecolab (ECL) Stock Valuation: Is the 50% Three-Year Gain Justified?
    June 13, 2026, 12:36 AM EDT. Ecolab (ECL) has gained 50% over three years but currently trades at US$265.41, raising questions about its valuation. A Discounted Cash Flow (DCF) analysis estimates fair value at about US$207.58, suggesting the stock is overvalued by 27.9%. Ecolab scores low on a six-point valuation checklist, indicating potential red flags. Despite steady returns and a strong industry position, investors should carefully assess if current prices reflect genuine growth prospects or inflated market sentiment. The stock's Price-to-Earnings (P/E) ratio and other valuation metrics warrant further scrutiny to determine whether Ecolab remains a reasonable investment at present levels.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next
Next Story

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next

Go toTop